Compare PAX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | STOK |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | 2019 |
| Metric | PAX | STOK |
|---|---|---|
| Price | $11.95 | $35.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $20.00 | ★ $36.10 |
| AVG Volume (30 Days) | ★ 998.6K | 589.0K |
| Earning Date | 01-01-0001 | 04-15-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $36,555,000.00 |
| Revenue This Year | $13.00 | $428.68 |
| Revenue Next Year | $15.87 | N/A |
| P/E Ratio | ★ $25.65 | $40.67 |
| Revenue Growth | N/A | ★ 316.34 |
| 52 Week Low | $9.44 | $5.35 |
| 52 Week High | $17.80 | $39.81 |
| Indicator | PAX | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 20.89 | 57.06 |
| Support Level | $10.12 | $30.50 |
| Resistance Level | $14.53 | $35.75 |
| Average True Range (ATR) | 0.48 | 2.31 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 6.44 | 49.89 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.